| |
Intervention(s) (route, frequency, total dose/day) |
Comparator(s) (route, frequency, total dose/day) |
| Choi 1995 |
I1: KRG (tablet, NR, 1800 mg) |
C1: Placebo (NR in detail) |
| C2: Trazodon (tablet, 25 mg daily at bedtime) |
| Choi 1999 |
I1: KRG (tablet, 3 times, 1800 mg) |
C1: Placebo (tablet, 3 times, same shape) |
| Choi 2001 |
I1: KRG (tablet, 3 times, 1800 mg) |
C1: Placebo (same shape) |
| Choi 2003 |
I1: KRG (tablet, 3 times, 1800 mg) |
C1: Placebo (NR in detail) |
| de Andrade 2007 |
I1: KRG (capsule, 3 times, 3000 mg) |
C1: Placebo (capsule containing starch with KRG flavour) |
| Ham 2009 |
I1: KRG plus ginsenoside (capsule, 2 times, 800 mg) |
C1: Placebo (capsule, microcrystalline cellulose 200 mg) |
| Hong 2002 |
I1: KRG (NR, 3 times, 2700 mg) |
C1: Placebo (NR in detail) |
| Kim 1999 |
I1: KRG (capsule, 3 times, 2700 mg) |
C1: Placebo (same shape and smell) |
| Kim 2009 |
I1: Tissue‐cultured mountain ginseng (TCMG) (NR, 2 times, 2000 mg) |
C1: Placebo (NR in detail) |
|
C: comparator; I: intervention; KRG: Korean red ginseng; TCMG:Tissue‐cultured mountain ginseng; NR: not reported. |
